19217-50-6

Usage

Uses

Used in Flavoring Industry:
3-Methoxy-4-methylphenol is used as a flavoring agent in food and beverages, adding a distinct aromatic taste and enhancing the overall flavor profile.
Used in Pharmaceutical Industry:
3-Methoxy-4-methylphenol is used as an active ingredient in pharmaceuticals, particularly in the production of cough syrups and throat lozenges, due to its antiseptic and expectorant properties. It helps alleviate symptoms of respiratory infections and promotes easier expectoration.
Used in Fragrance Industry:
3-Methoxy-4-methylphenol is used as a precursor in the production of various fragrances, contributing to the creation of unique and appealing scents for perfumes, cosmetics, and other scented products.
Used in Organic Synthesis:
3-Methoxy-4-methylphenol is used as a reagent in organic synthesis, enabling the production of a wide range of chemical compounds and intermediates for various applications.
Used in Research:
3-Methoxy-4-methylphenol has been studied for its potential anti-inflammatory and antioxidant effects, indicating its potential use in the development of new therapeutic agents and treatments for various conditions.

Upstream product

• 16452-01-0 ortho-cresidine 
• 496-73-1 4-methyl resorcinol 
• 77-78-1 dimethyl sulfate 
• 18278-34-7 4-hydroxy-2-methoxybenzaldehyde 
• 13120-77-9 2-methyl-5-nitroanisole 

Downstream Products

• 101257-48-1 5-methoxy-4-methyl-2-nitrophenol 
• 101870-29-5 2-amino-5-methoxy-4-methylphenol 
• 50342-31-9 1,5-dimethoxy-2-methyl-4-nitrobenzene 
• 850793-85-0 C₂₀H₂₂O₄ 
• 1311138-22-3 1,1-dimethylethyl ((1R)-1-{[(6-{[4-methyl-3-(methyloxy)phenyl]oxy}-3-pyridinyl)amino]carbonyl}propyl)carbamate 
• 1311138-23-4 (2R)-2-amino-N-(6-{[4-methyl-3-(methyloxy)phenyl]oxy}-3-pyridinyl)butanamide 
• 1311138-25-6 1,1-dimethylethyl ((1S)-1-{[(6-{[4-methyl-3-(methyloxy)phenyl]oxy}-3-pyridinyl)amino]carbonyl}propyl)carbamate 
• 1311138-26-7 (2S)-2-amino-N-(6-{[4-methyl-3-(methyloxy)phenyl]oxy}-3-pyridinyl)butanamide 
• 1311138-50-7 1,1-dimethylethyl ((1R)-2,2-dimethyl-1-{[(6-{[4-methyl-3-(methyloxy)phenyl]oxy}-3-pyridinyl)amino]carbonyl}propyl)carbamate 
• 1311138-51-8 3-methyl-N'-(6-{[4-methyll-3-(methyloxy)phenyl]oxy}-3-pyridinyl)-D-valinamide 
• 1311138-52-9 1,1-dimethylethyl ((1R)-1-methyl-1-{[(6-{[4-methyl-3-(methyloxy)phenyl]oxy}-3-pyridinyl)amino]carbonyl}propyl)carbamate 
• 1311138-54-1 1,1-dimethylethyl (1-{[(6-{[4-methyl-3-(methyloxy)phenyl]oxy}-3-pyridinyl)amino]carbonyl}cyclobutyl)carbamate 
• 1311138-55-2 1-amino-N-(6-{[4-methyl-3-(methyloxy)phenyl]oxy}-3-pyridinyl)cyclobutanecarboxamide 
• 1311136-73-8 (5R)-5-methyl-3-(4-{[4-methyl-3-(methyloxy)phenyl]oxy}phenyl)-2,4-imidazolidinedione 

Relevant academic research and scientific papers

Ceria-promoted Co@NC catalyst for biofuel upgrade: synergy between ceria and cobalt species

Ceria-promoted Co@NC (NC, N doped carbon) catalysts are prepared by pyrolysis of biomass materials. Characterization results indicate that ceria and Co species facilitate the distribution of each other due to the formation of a Ce-O-Co solid solution. The specific surface area of the catalyst increased from 378.77 to 537.7 m2g?1viathe introduction of ceria. The electron transfer from Co to Ce further enhanced their interaction, and Co species facilitate the formation of more defective oxygen vacancies on ceria, which are beneficial to the activities of catalytic hydrogenation and catalytic transfer hydrogenation (CTH), respectively. Thus, Co/Ce@NC (0.99% Co loading) pyrolyzed at 850 °C exhibits excellent performance in the hydrodeoxygenation (HDO) of vanillin with high metal utilization. Catalytic hydrogenation and CTH coexisted in the presence of H2and ethanol, and >99% yield of creosol can be obtained in each of them. The reaction processes are monitored. No intermediate is found in aqueous media, while ethoxymethyl-4-methoxy-2-phenol is detected in ethanol. Moreover, Co/Ce@NC presents outstanding stability and general applicability. This work provides new insights into the construction of M@NC (M, metal) catalysts and the HDO process of biofuel upgrade.

SUBSTITUTED-N-HETEROARYL COMPOUNDS AND USES THEREOF

The present disclosure relates generally to compounds useful for the treatment and/or enhancement of cognitive function and negative symptoms associated with central nervous system disorders where the circuitry involving fast spiking PV+ interneurons and the production of cortical gamma oscillations is disrupted. The subject disclosure enables the manufacture of medicaments as well as compositions containing same for use in methods of therapy and prophylaxis of cognitive dysfunction and negative symptoms.

SUBSTITUTED-PYRIDINYL COMPOUNDS AND USES THEREOF

The present application relates generally to compounds useful for the treatment and/or enhancement of cognitive dysfunction and negative symptoms associated with CNS disorders where the circuitry involving fast spiking PV+ interneurons and the production of cortical gamma oscillations is disrupted. The subject disclosure enables the manufacture of medicaments as well as compositions containing same for use in methods of therapy and prophylaxis of cognitive dysfunction and negative symptoms.

HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS

The invention provides compounds of formula (I): Said compounds being inhibitors of Kv3 channels and of use in the prophylaxis or treatment of related disorders.

HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS

The invention provides compounds of formula (I): Said compounds being inhibitors of Kv3 channels and of use in the prophylaxis or treatment of related disorders.

IMIDAZOLIDINEDIONE DERIVATIVES

The invention provides a compound of formula (Ia), and pharmaceutically acceptable salts thereof. The invention also provides use of the compounds or salts as modulators of Kv3.1 and/or Kv3.2, and in the treatment of diseases or disorders where a modulator of Kv3.1 and/or Kv3.2 is required, such as depression and mood disorders, hearing disorders, schizopherenea, substance abuse disorders, sleep disorders or epilepsy.

PHENOXYETHER DERIVATIVES AS PPAR MODULATORS

The present invention is directed to a compound of formula (I), or a pharmaceutically acceptable salt, solvate, hydrate or stereoisomer thereof, which is useful in treating or preventing disorders mediated by a peroxisome proliferator activated receptor (PPAR), such as syndrome X, type II diabetes, hyperglycemia, hyperlipidemia, obesity, coagaulopathy, hypertension, arteriosclerosis, and other disorders related to syndrome X and cardiovascular diseases.